CHRM4

Muscarinic acetylcholine receptor M4 · P08173 · CHRM4 on Sugi Atlas →

260,837 patent compounds predicted against CHRM4, 136,718 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dimethindene (SCHEMBL18759)	1.00	19/20
Diphenidol (SCHEMBL34469)	1.00	11/20
Oxapium (SCHEMBL24857)	0.41	10/20
Carbamoylcholine (SCHEMBL2792)	1.00	7/20
Acetylcholine (SCHEMBL3216)	1.00	7/20
Suxamethonium (SCHEMBL41537)	0.65	7/20
Methylbenactyzium (SCHEMBL60901)	1.00	6/20
SCHEMBL26032	0.86	6/20
Drofenine (SCHEMBL25124)	0.59	6/20
Carbamoylcholine (SCHEMBL2791)	1.00	5/20
Ipratropium (SCHEMBL3124)	1.00	5/20
Ipratropium (SCHEMBL3125)	1.00	5/20
Olanzapine (SCHEMBL28763)	1.00	5/20
Trihexyphenidyl (SCHEMBL34645)	1.00	5/20
Trihexyphenidyl (SCHEMBL34646)	1.00	5/20
Biperiden (SCHEMBL34957)	1.00	5/20
Biperiden (SCHEMBL40777)	1.00	5/20
Biperiden (SCHEMBL40776)	0.98	5/20
Acetylcholine (SCHEMBL40885)	0.95	5/20
Biperiden (SCHEMBL41834)	0.82	5/20

Clinical trials — most relevant to CHRM4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Metoclopramide as Treatment of Clozapine-induced Hypersalivation	PHASE3	COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	PHASE2	COMPLETED
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia	PHASE2	COMPLETED
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	PHASE1	NOT_YET_RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants	PHASE1	COMPLETED
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing	PHASE1	COMPLETED
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care	PHASE1	COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine	PHASE1	WITHDRAWN
Cholinergic Mechanisms of Attention in Aging	EARLY_PHASE1	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Mental Ability Challenge Study in Adults With and Without HIV	nan	COMPLETED
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Brain Nicotine Receptor Density in Veteran Smokers	nan	COMPLETED
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease	nan	COMPLETED
Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRM4 binder may also engage these)

Protein	Name	Similarity
P32211	—	1.000	P32211 →
P08485	—	1.000	P08485 →
P17200	—	0.997	P17200 →
P30544	—	0.989	P30544 →
P10980	—	0.984	P10980 →
P41985	—	0.982	P41985 →
P06199	—	0.981	P06199 →
Q9ERZ4	—	0.981	Q9ERZ4 →
P30372	—	0.979	P30372 →
CHRM2	Muscarinic acetylcholine receptor M2	0.974	landscape →
Q868T3	—	0.973	Q868T3 →
P56490	—	0.969	P56490 →
P56489	—	0.968	P56489 →
P04761	—	0.968	P04761 →
Q9N2A7	—	0.968	Q9N2A7 →
Q91559	—	0.967	Q91559 →
CHRM5	Muscarinic acetylcholine receptor M5	0.967	landscape →
P08482	—	0.967	P08482 →
Q5IS53	—	0.965	Q5IS53 →
P08911	—	0.965	P08911 →
Q920H4	—	0.965	Q920H4 →
Q5R949	—	0.964	Q5R949 →
Q5IS98	—	0.964	Q5IS98 →
P12657	—	0.964	P12657 →
CHRM1	Muscarinic acetylcholine receptor M1	0.964	landscape →
A1ZAX0	—	0.963	A1ZAX0 →
Q9WTV8	—	0.962	Q9WTV8 →
O62809	—	0.962	O62809 →
Q9WTV9	—	0.960	Q9WTV9 →
Q9N2A4	—	0.960	Q9N2A4 →